Patent Assignment
Reel/Frame 050797/0533
Change of Name and Address
Recorded: 2019-10-23
Pages: 10
Assignor
KYOWA HAKKO KIRIN CO., LTD.
Executed: 2019-07-01
Assignee
KYOWA KIRIN CO., LTD.
1-9-2, OTEMACHI, CHIYODA-KU,, TOKYO, 100-0004, JAPAN
Covered Properties
(171)
Alpha-1,3-Fucosyltransferase
Patent:
7,094,530 →
Application:
08/361,306 →
Human Anti-CD40 Antibodies
Process for Purifying Antibody
Cells Producing Antibody Compositions with Increased Antibody Dependent Cytotoxic Activity
Process for producing carbohydrates using beta 1,3-N-acetyl-glucosaminyltransferase
Patent:
7,005,279 →
Application:
10/019,735 →
Powder Material Spraying Device
Patent:
6,776,361 →
Application:
10/019,936 →
Process for Producing Polypeptide
Patent:
7,504,256 →
Application:
10/110,997 →
Quinoline Derivatives and Quinazoline Derivatives Having Azolyl Group
Anti-Human Vegf Receptor Flt-1 Monoclonal Antibody
Constant Volume Delivery Device and Method of Delivering Powder Material
Methods Using Eosinophil-Specific Apoptosis Inducer
Coating Device for Powder Material
Antibody Composition-Containing Medicament
Cells in Which Activity of the Protein Involved in Transportation of Gdp-Fucose Is Reduced or Lost
Pulsating Vibration Air Generation Apparatus
Antibody Against Fibroblast Growth Factor-23
Adenosine A2A Receptor Antagonists for Treating Restless Legs Syndrome or Nocturnal Myoclonus
Method of Stabilizing Diarylvinylene Compound
N-{2-Chloro-4-[(6,7-Dimethoxy-4-Quinolyl)Oxy]Phenyl}-N'-(5-Methyl-3-Isoxazolyl)Urea Salt in Crystalline Form
Method of Treating an Anxiety Disorder
Microcrystal
HSP90 Family Protein Inhibitors
Pharmaceutical Composition
Method of stabilizing antibody and stabilized solution-type antibody preparation
Medicament Comprising Recombinant Antibody Against Chemokine Receptor CCR4
Method of Treating Transplant Rejection with an Anti-CD40 Antibody
Thiazole Derivatives
Agents for Treating Migraine
Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
Anti-CD40 Monoclonal Antibody
Method of Producing Recombinant Antithrombin Iii Composition
Method for Treating TH2-Mediated Disease
Method of Modulating the Activity of Functional Immune Molecules
Methods for Producing Antibody Compositions with Increased Adcc
Antibody Composition-Producing Cell
Antibody Composition Exhibiting Increased Cellular Cytotoxicty Due to Glycosylation
Anti-Human Vegf Receptor Flt-1 Monoclonal Antibody
Mammalian Host Cell Modified by Rnai to Inhibit a 1,6-Fucosyltransferase.
Antibody Composition-Producing Cell
Administering Adenosine A2A Receptor Antagonist to Reduce or Suppress Side Effects of Parkinson's Disease Therapy
Methods of Treating Patients Suffering from Movement Disorders
Recombinant Antibody Composition
Composition Improved in the Solubility or Oral Absorbability
Anti-CD40 Monoclonal Antibody
Stabilized Human IGG4 Antibodies
Method of Modulating the Activity of Functional Immune Molecules to Vascular Endothelial Growth Factor Receptor
Method of Modulating the Activity of Functional Immune Molecules to Platelet-Derived Growth Factor Receptor
Method of Modulating the Activity of Functional Immune Molecules to CD4
Method of Modulating the Activity of Functional Immune Molecules to CXCR4 Protein
Method of Modulating the Activity of Functional Immune Molecules to GM2
Method of Modulating the Activity of Functional Immune Molecules to CD52
Method of Modulating the Activity of Functional Immune Molecules to Her-2
Stabilized Human IGG2 and IGG3 Antibodies
Igf-1R Inhibitor
Therapeutic and/or Preventive Agents for a Sleep Disorder
Effector Function Enhanced Recombinant Antibody Composition
Method of Producing Sugar Chain Using Human G4 Polypeptide
Antibody Composition-Producing Cell with Inactivated A-1,6-Fusocyltransferase
ANTIBODY COMPOSITION-PRODUCING CELL IN WHICH ENZYME EXPRESSION IS INHIBITED BY RNAi
Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same
Human Artificial Chromosome (Hac) Vector and Human Cell Medicine Comprising Same
Method for Treating Hypophosphatemic Bone Diseases Using Fgf-23 Antibody
Glycoengineered, Recombinant Antibody to Ccr-4 with Reduced Fucosylation
Glycoengineered, Recombinant Antibody
Process for Producing Polypeptide
Human Cdr-Grafted Antibody and Antibody Fragment Thereof
Cells with Altered Fucosylation and Producing Antibodies Therefrom
HSP90 Family Protein Inhibitors
Antagonistic Human Light-Specific Human Monoclonal Antibodies
Imidazole Derivatives
Anti-CD27 Antibody
Anti-System Asc Amino Acid Transporter 2 (ASCT2) Antibody
Method of Enhancing of Binding Activity of Antibody Composition to Fcgamma Receptor Iiia
Method for Producing Antithrombin Composition
Pyrimidodiazepinone Derivative
Method of Modulating the Activity of Functional Immune Molecules
Anti-CD4 Antibody
Vaccinia Virus H3L and B5R Specific Monoclonal Antibodies and Methods of Making and Using Same
Method for Treating the TH2-Mediated Disease
Thiazole Derivatives
Cells in Which Activity of the Protein Involved in Transportation of Gdp-Fucose Is Reduced or Lost
Protein Production Method
Antibody Composition Exhibiting Cellular Cytotoxicity Due to Glycosylation and Containing Ganglioside GM2 Binding Antibody
Recombinant Antibody Composition
ANTI-Aß OLIGOMER HUMANIZED ANTIBODY
Anti-Abeta Oligomer Humanized Antibody
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds to CCR4
Human Artificial Chromosome (Hac) Vector
Human Cdr-Grafted Antibody and Antibody Fragment Thereof
Thiazole Derivatives
Anti-CD27 Humanized Monoclonal Antibody
Stable Multivalent Antibody
Anti System Asc Amino Acid Transporter 2 (ASCT2) Antibody
Composition for Suppressing Expression of Target Gene
Antibody Variants Composition
Novel Antibody and Antibody Fragment Introduced New Modification Sites
Antibody Composition-Producing Cell
Anti-Tim-3 Antibody
Methods for Synthesizing Sugar Chains Using B1,3-N-Acetylglucosaminyl Transferase
Effector Function Enhanced Recombinant Antibody Composition
Pharmaceutical Composition
Antagonistic Human Light-Specific Human Monoclonal Antibodies
Method for Treatment of Blood Tumor Using Anti-Tim-3 Antibody
Agonistic Anti-CD40 IGG2 Antibodies Having Amino Acid Mutations Introduced Therein
Antibody to Human Il-3 Receptor Alpha Chain
Process for Production of Protein
Sterol Derivative
Method of Treating an Anxiety Disorder
Method for Producing Recombinant Antibody and Antibody Fragment Thereof
Agonist Antibody to Human Thrombopoietin Receptor
Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same
Cationic Lipid
Antibody Composition-Producing Cell
Anti-A(Beta) Oligomer Humanized Antibody
Anti-CD4 Antibody
Orally Disintegrating Tablet
Method of Purifying Protein
Thiazole Derivatives
Human Cdr-Grafted Antibody and Antibody Fragment Thereof
Pharmaceutical Composition Containing Kw-6002 and Fluoxetine or Paroxentine
Pharmaceutical Composition for Treating Bone Diseases Which Comprises Protein Comprising FRIZZLED1, FRIZZLED2 or FRIZZLED7 Extracellular Cysteine-Rich Domain
Antagonistic Human Light-Specific Human Monoclonal Antibodies
Antibody to Human Il-3 Receptor Alpha Chain
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds to CCR4
Method of Stabilizing Antibody and Stabilized Solution-Type Antibody Preparation
Medicament Comprising Recombinant Antibody Against Chemokine Receptor CCR4
Pharmaceutical Agent Comprising Anti-BMP9 Antibody as Active Ingredient for Treatment of Anemia Such as Renal Anemia and Cancer Anemia
Therapeutic Method and Medicament for Htlv-1 Associated Myelopathy
Method for Preparing Aqueous Solution Containing Culture Medium and Chelating Agent
Ring-Fused Heterocyclic Derivative
Method for Producing Proteins
Highly Concentrated Anti-CD40 Antibody Pharmaceutical Preparation
Methods of Treating Autoimmune Disease with Anti-CD40 Antibodies
Anti-Tim-3 Antibody
Heterodimer Protein Composition
Anti-FOLR1 Antibody
Pyrimidodiazepinone Compound
Protein Comprising Truncated Form of Extracellular Region Protein of FRIZZLED2, and Pharmaceutical Composition for Treating Bone Diseases Which Comprises Said Protein
Method for Purifying Protein
Method for Treatment of Blood Tumor Using Anti-Tim-3 Antibody
Vaccinia Virus H3L and B5R Specific Monoclonal Antibodies and Methods of Making and Using Same
Method of Modulating the Activity of Functional Immune Molecules
Human Cdr-Grafted Antibody and Antibody Fragment Thereof
Methods for Producing Stabilized Human IGG2 and IGG3 Antibodies
Methods for Treating Transplant Rejection by Administering Anti-CD40 Antibody
4,6-Hexadecadiene-2,4-Dicarboxylic Acid Derivative
Ring-Fused Heterocyclic Compound
Method for Preventing Reduction of Polypeptide by Adding Amino Acid to Culture Solution
Recombinant Antibody Composition
Anti-CD40 Antibody Mutants
Antibody Composition-Producing Cell
Stabilized Human IGG4 Antibodies
Antagonistic Human Light-Specific Human Monoclonal Antibodies
Pharmaceutical Composition Comprising Antibody Composition Which Specifically Binds to CCR4
Method of Stabilizing Antibody and Stabilized Solution-Type Antibody Preparation
Protein Production Method
Human Cdr-Grafted Antibody and Antibody Fragment Thereof
Method for Treatment of Blood Tumor Using Anti-Tim-3 Antibody
Novel Antibody and Antibody Fragment Introduced New Modification Sites
Anti-FOLR1 Antibody
Wnt Signaling Inhibitor
DNA ENCODING AN ANTI-CD40 IgG2 ANTIBODY HAVING AMINO ACID MUTATIONS
Polynucleotide Encoding Antibody to Human Il-3 Receptor Alpha Chain
Antibody Composition-Producing Cell
Method for Treatment of Blood Tumor Using Anti-Tim-3 Antibody
Human Monoclonal Antibody Human CD134 (OX40) and Methods of Making and Using Same
Method for Measuring Toxicity of Human Csf
Antibody Which Specifically Binds to Human CRTH2
Antibody Variants Composition
Therapeutic Method and Medicament for Htlv-1 Associated Myelopathy
Antibody Which Specifically Binds to Human CRTH2
Related Assignments
(3)
Other recorded transfers of the patents in this record — the chain of ownership.
Corrective Assignment to Correct the Fifth Assignor's Name Previously Recorded on Reel 027869 Frame 0069. Assignor(S) Hereby Confirms the Assignment of Assignors Interest.
Apr 27, 2012
From: UCHIDA, KENJI; AGATSUMA, TSUTOMU; HIBINO, KAZUHIRO; SASHO, SETSUYA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 028117/0503 →
Merger
May 26, 2021
From: KIRIN PHARMA COMPANY, LIMITED (A/K/A KIRIN PHARMA KABUSHIKI KAISHA)
To: KYOWA HAKKO KOGYO CO., LTD.
Reel/Frame 056351/0089 →
Corrective Assignment to Correct the Nature of Conveyance and Assignor's Name Previously Recorded on Reel 022390 Frame 0234. Assignor(S) Hereby Confirms the Change of Name.
May 26, 2021
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 056583/0647 →